French-American artificial intelligence company Owkin has launched an ambitious patient data mining initiative called ATLANTIS, partnering with 20 prestigious healthcare institutions across seven countries. The project, which commenced in September and will run until May 2025, represents a significant advancement in collaborative medical research and data analysis.
Global Partnership Network and Therapeutic Focus
The collaborative network spans healthcare institutions across France, Spain, Germany, Italy, the United States, the United Kingdom, and Israel. Notable UK participants include the Royal Marsden NHS Foundation Trust and Newcastle Upon Tyne NHS Foundation Trust. This international coalition will focus on 11 distinct therapeutic areas, strategically chosen to address critical medical needs.
The therapeutic scope encompasses:
- Seven oncology programs, including:
- Non-small cell lung cancer (NSCLC)
- Head and neck squamous cell carcinoma (HNSCC)
- Breast cancer
- Prostate cancer
- Ovarian cancer
- Pancreatic cancer
- Multiple myeloma (MM)
- Three immunology and inflammation conditions:
- Ulcerative colitis (UC)
- Crohn's disease (CD)
- Systemic lupus erythematosus (SLE)
- Neurological focus:
- Alzheimer's disease (AD)
Innovative Data Integration Approach
ATLANTIS will aggregate and analyze diverse data sources, including:
- Electronic health records
- Medical imaging
- Physician notes
- Diagnostic results
This comprehensive approach aims to dismantle traditional data silos, making previously inaccessible information available for research and analysis. The collected data will power Owkin K, the company's proprietary AI-driven operating software, designed to decode complex biological processes and streamline drug discovery and development.
Mutual Benefits and Early Success
Partner institutions will receive enhanced AI capabilities and valuable insights from their contributed data, supporting their individual research initiatives. "Owkin is committed to fostering collaboration between data scientists and patient data to achieve unparalleled insights and innovation," stated Agathe Arlotti, head of partnerships at Owkin.
The project has already shown promising results, with Owkin's affiliate company Epkin initiating the phase 1 INVOKE clinical trial. This trial investigates OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor developed using Owkin K in collaboration with Idorsia, targeting patients with solid tumors.
Strategic Impact on Medical Research
The ATLANTIS initiative represents a significant step forward in utilizing artificial intelligence for medical research. By combining extensive patient data with advanced AI capabilities, the project aims to accelerate:
- Medical research advancement
- Novel drug discovery
- Diagnostic tool development
- Treatment optimization across multiple therapeutic areas
